Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Ametinib combined with bevacizumab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Anlotinib
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Arm 1： Standard Synchronous Group
The First People's Hospital of Lianyungang
Advanced Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Azacitidine
Syndax Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
BL-B01D1
Sichuan Baili Pharmaceutical Co.,
Non-small Cell Lung Cancer
1 trial -
BNT116
Regeneron UK Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
Benmelstobart
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial -
CLN-081
Cullinan Therapeutics
Non Small Cell Lung Cancer
1 trial -
CT053PTSA
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non-small Cell Lung Cancer
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Non-small Cell Lung Cancer Stage III
1 trial -
Chemotherapy + immunotherapy
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
1 trial -
DS-1062a
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Docetaxel
Takeda
Non-small Cell Lung Cancer
1 trial -
Docetaxel
Hospital Authority, Hong Kong
Non Small Cell Lung Cancer
1 trial -
Domvanalimab
Arcus Biosciences
Non Small Cell Lung Cancer
2 trials -
Domvanalimab
Arcus Biosciences
Advanced Non-Small Cell Lung Cancer
1 trial -
Durvalumab + Oleclumab
MedImmune
Stage III Non-small Cell Lung Cancer
1 trial -
Elironrasib
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Ensartinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals
Non Small Cell Lung Cancer
2 trials -
Erlotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small-cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.